CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations

TÜBINGEN, Germany / BOSTON, MA, May 12, 2018 – CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the appointment of Matthew L. S. Beck as Vice President, Investor Relations. He joins CureVac from Solebury Trout, a leading investor relations firm focused on companies in the life sciences and other industries.

"We're excited to welcome Matt to the CureVac team," said Pierre Kemula, Chief Financial Officer, CureVac AG. "His experience advising senior management at numerous life sciences companies, and knowledge of the capital markets in the U.S., will be critical as we advance our business and clinical pipeline of mRNA-based therapies.”

Mr. Beck has more than 18 years of experience in the field of investor relations. Prior to serving as Senior Vice President at Solebury Trout, he was Senior Specialist at NASDAQ OMX’s Corporate Advisory division. Prior to NASDAQ OMX, he served as a Marketing Associate at Dunbar Capital, a fund of hedge funds. Prior to that, he was a Vice President in Goldman Sachs’ NYSE DMM division. Early in his career, Mr. Beck served in increasingly responsible roles at Thomson Financial. He earned a Bachelor of Arts degree in Political Science from Vassar College.

Download press release as PDF file.